{"disease":{"id":"hcc-hepatocellular-carcinoma","name":"hcc hepatocellular carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04371042","title":"PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06776185","title":"Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Chen Xiaoping","has_results":false},{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07444905","title":"Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1523,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07109336","title":"Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":790,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT07141056","title":"The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Guilin Medical University, China","has_results":false},{"nct_id":"NCT06184152","title":"CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT07495735","title":"Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06483594","title":"Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT07058649","title":"Downstaging Prediction Model for HCC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":369,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"GV20 Therapeutics","has_results":false},{"nct_id":"NCT07157969","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07001085","title":"ctDNA Monitoring in Patients With HCC and mCRC","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT06934070","title":"Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":287,"lead_sponsor_name":"Qiang Xu","has_results":false},{"nct_id":"NCT06805552","title":"Sarcopenia and Systemic Therapy in HCC","phase":"","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06760494","title":"Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07351669","title":"A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06631326","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT07412054","title":"Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":234,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05665348","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT07475026","title":"A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":198,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07376707","title":"A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Hefei TG ImmunoPharma Co., Ltd.","has_results":false},{"nct_id":"NCT06437457","title":"Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT07489768","title":"GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":162,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06527495","title":"Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05202015","title":"Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT06984718","title":"A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT05651022","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Indaptus Therapeutics, Inc","has_results":false},{"nct_id":"NCT07117279","title":"A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predicting Conversion Therapy Response in Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07410715","title":"Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma (SWITCH)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06712017","title":"Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"GrandPharma (China) Co., Ltd.","has_results":false},{"nct_id":"NCT06602986","title":"Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":96,"lead_sponsor_name":"Pak Emirates Military Hospital","has_results":false},{"nct_id":"NCT06991907","title":"PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Jiangxi Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT07310173","title":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Zhejiang Hisun Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT07187284","title":"EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT06653023","title":"Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Wondercel Biotech (ShenZhen)","has_results":false},{"nct_id":"NCT06958484","title":"Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT07518706","title":"Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06777017","title":"Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06999707","title":"Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06999694","title":"Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06375317","title":"HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Yehua Shen","has_results":false},{"nct_id":"NCT07306481","title":"The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT07521852","title":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"TaiRx, Inc.","has_results":false},{"nct_id":"NCT06999837","title":"[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06617000","title":"A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"SCG Cell Therapy Pte. Ltd.","has_results":false},{"nct_id":"NCT06045975","title":"Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06884982","title":"An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Northern Jiangsu People's Hospital","has_results":false},{"nct_id":"NCT07305428","title":"Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07145801","title":"Y-90 Treatment Response Using Transarterial Radioembolization","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Thomas Jefferson University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}